Fact Sheet for Patients, Parents & Caregivers (English)

Fact Sheet for Patients, Parents and Caregivers Emergency Use Authorization (EUA) of Bamlanivimab for Coronavirus Disease 2019 (COVID-19) You are being given a medicine called bamlanivimab for the treatment of coronavirus disease 2019 (COVID- 19). This Fact Sheet contains information to help you understand the potential risks and potential benefits of taking bamlanivimab, which you may receive. Receiving bamlanivimab may benefit certain people with COVID-19. Read this Fact Sheet for information about bamlanivimab. Talk to your healthcare provider if you have questions. It is your choice to receive bamlanivimab or stop it at any time. What is COVID-19? COVID-19 is caused by a virus called a coronavirus. People can get COVID-19 through contact with another person who has the virus. COVID-19 illnesses have ranged from very mild (including some with no reported symptoms) to severe, including illness resulting in death. While information so far suggests that most COVID-19 illness is mild, serious illness can happen and may cause some of your other medical conditions to become worse. People of all ages with severe, long-lasting (chronic) medical conditions like heart disease, lung disease, and diabetes, for example, seem to be at higher risk of being hospitalized for COVID-19. What are the symptoms of COVID-19? The symptoms of COVID-19 include fever, cough, and shortness of breath, which may appear 2 to 14 days after exposure. Serious illness including breathing problems can occur and may cause your other medical conditions to become worse. What is bamlanivimab? Bamlanivimab is an investigational medicine used for the treatment of COVID-19 in non-hospitalized adults and adolescents 12 years of age and older with mild to moderate symptoms who weigh 88 pounds (40 kg) or more, and who are at high risk for developing severe COVID-19 symptoms or the need for hospitalization. Bamlanivimab is investigational because it is still being studied. There is limited information known about the safety or effectiveness of using bamlanivimab to treat people with COVID-19. The FDA has authorized the emergency use of bamlanivimab for the treatment of COVID-19 under an Emergency Use Authorization (EUA). For more information on EUA, see the section “What is an Emergency Use Authorization (EUA)?” at the end of this Fact Sheet. What should I tell my healthcare provider before I receive bamlanivimab? Tell your healthcare provider about all of your medical conditions, including if you:  Have any allergies  Are pregnant or plan to become pregnant  Are breastfeeding or plan to breastfeed  Have any serious illnesses  Are taking any medications (prescription, over-the-counter, vitamins, and herbal products) How will I receive bamlanivimab?  Bamlanivimab is given to you through a vein (intravenous or IV) for at least 1 hour.  You will receive one dose of bamlanivimab by IV infusion. What are the important possible side effects of bamlanivimab? Possible side effects of bamlanivimab are:  Allergic reactions. Allergic reactions can happen during and after infusion with bamlanivimab. Tell your healthcare provider right away if you get any of the following signs and symptoms of allergic reactions: fever, 1